PALB2 and breast carcinoma: In a recent study of breast cancer patients who underwent MGPT, 31.8% (n = 7/22) of MBC cases tested positive for pathogenic or likely pathogenic variants: BRCA1 (1), BRCA2 (3), PALB2 (1), CHEK2 (1), and ATM (1) [8].